Loading…
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-177M | $-191M | $-150M | -65.3% | -100.0% | -25.9% |
| 2024 | $0M | $-243M | $-258M | $-201M | -61.0% | -76.8% | -21.3% |
| 2023 | $0M | $-313M | $-327M | $-239M | -63.9% | -39.1% | -3.9% |
| 2022 | $0M | $-321M | $-340M | $-226M | -51.0% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0.16 | 0.10 | 0.02 | 0 |
| Operating Revenue | - | 0.16 | 0.10 | 0.02 | 0 |
| Operating Expense | - | 335.69 | 314.59 | 257.50 | 206.93 |
| Research And Development | - | 256.39 | 242.91 | 192.30 | 150.15 |
| Selling General And Administration | - | 79.31 | 71.67 | 65.20 | 56.78 |
| Total Expenses | - | 335.69 | 314.59 | 257.50 | 206.93 |
| Operating Income | - | -335.54 | -314.49 | -257.48 | -206.93 |
| Total Operating Income As Reported | - | -335.54 | -327.74 | -273.20 | -209.32 |
| EBITDA | - | -321.24 | -313.07 | -243.33 | -177.45 |
| Normalized EBITDA | - | -321.24 | -299.82 | -227.61 | -175.07 |
| EBIT | - | -335.54 | -327.26 | -256.97 | -189.81 |
| Interest Income | - | 4.57 | 18.31 | 20.15 | 19.29 |
| Interest Expense | - | - | 0 | 0.18 | 1.08 |
| Net Interest Income | - | 4.57 | 18.31 | 19.97 | 18.21 |
| Other Non Operating Income Expenses | - | -9.44 | -17.84 | -3.92 | 0.22 |
| Other Income Expense | - | -9.44 | -31.08 | -19.64 | -2.17 |
| Interest Income Non Operating | - | 4.57 | 18.31 | 20.15 | 19.29 |
| Interest Expense Non Operating | - | - | 0 | 0.18 | 1.08 |
| Net Non Operating Interest Income Expense | - | 4.57 | 18.31 | 19.97 | 18.21 |
| Pretax Income | - | -340.41 | -327.26 | -257.15 | -190.89 |
| Tax Provision | 0 | - | 0 | 0.44 | 0 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | -3.30 | 0 |
| Net Income Continuous Operations | - | -340.41 | -327.26 | -257.59 | -190.89 |
| Net Income From Continuing And Discontinued Operation | - | -340.41 | -327.26 | -257.59 | -190.89 |
| Net Income From Continuing Operation Net Minority Interest | - | -340.41 | -327.26 | -257.59 | -190.89 |
| Net Income | - | -340.41 | -327.26 | -257.59 | -190.89 |
| Net Income Common Stockholders | - | -340.41 | -327.26 | -257.59 | -190.89 |
| Net Income Including Noncontrolling Interests | - | -340.41 | -327.26 | -257.59 | -190.89 |
| Normalized Income | - | -340.41 | -314.02 | -245.17 | -188.50 |
| Diluted NI Availto Com Stockholders | - | -340.41 | -327.26 | -257.59 | -190.89 |
| Basic Average Shares | 135.82 | 143.15 | 156.93 | 194.81 | - |
| Diluted Average Shares | 135.82 | 143.15 | 156.93 | 194.81 | - |
| Reconciled Depreciation | - | 14.30 | 14.20 | 13.64 | 12.36 |
| Total Unusual Items | - | - | -13.24 | -15.72 | -2.38 |
| Total Unusual Items Excluding Goodwill | - | - | -13.24 | -15.72 | -2.38 |
| Special Income Charges | - | - | -13.24 | -15.72 | -2.38 |
| Impairment Of Capital Assets | - | - | 13.24 | 15.72 | 2.38 |
| General And Administrative Expense | - | 79.31 | 71.67 | 65.20 | 56.78 |
| Other Gand A | - | 79.31 | 71.67 | 65.20 | 56.78 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Allogene Therapeutics, Inc.this co. | ALLO | $704M | -3.69 | 2.41 | -65.3% | -4.15 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 | 8.91 | -14.9% | -46.77 |
| Solid Biosciences Inc. | SLDB | $713M | -4.09 | 3.96 | -96.8% | -3.80 |
| CBLL | CBLL | $711M | -13.32 | 4.58 | -34.4% | -13.81 |
| Enhabit, Inc. | EHAB | $707M |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| -153.68 |
| 1.32 |
| -0.9% |
| 20.09 |
| Aura Biosciences, Inc. | AURA | $703M | -6.62 | 5.13 | -77.6% | -5.92 |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Design Therapeutics, Inc. | DSGN | $672M | -9.63 | 3.16 | -32.8% | -8.33 |
| CorMedix Inc. | CRMD | $670M | 4.13 | 1.65 | 40.0% | 4.01 |
| Peer Median | - | -11.47 | 4.27 | -33.6% | -7.12 | |